Saturday, July 12, 2014 7:49:01 PM
Stock Tickers
US:BNIKF (OTC) & BTEBY (ADR)
Australian: ASX:BLT
If you are new Benitec, this post has the majority of due diligence nuggets dug out for you, so that you don’t have to. Welcome to Benitec Biopharma Ltd!
Benitec has commenced its clinical trial of TT-034 for the treatment of Hepatitis C on May 28, 2014. This treatment is supposed to be pan-genotype, gene-silencing, no-side effect, one-shot cure to cure Hepatitis C in hopefully 10 days, with continuing effects of the treatment for up to 150 days or so. The PR release on first dosing is here: http://www.benitec.com/documents/140529HEPATITISCPATIENTDOSINGCOMMENCEDFINAL.pdf
The above document will detail the timeline of future escalated dosing, in order to determine safety first, and then efficacy.
Clinical Trials on ClinicalTrials.gov can be seen here:http://www.clinicaltrial.gov/ct2/show/NCT01899092?term=tt-034&rank=1
For more information on dosing timlines, please see: http://www.irasia.com/listco/au/benitec/press/p140711.htm
For a more scientific review regarding TT-034 as a recombinant adeno-associated virus serotype 8 (AAV8) agent used in the treatment of diseases (More specifically HCV in this case), can be seen here:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951910/
It is probable that an update of the TT-034 clinical trial may be made on July 19, 2014, specifically regarding the first patient and safety.
In March, Benitec released their Spotlight Presentation in PDF format. That presentation can be seen here:
http://www.asx.com.au/spotlight/london/documents/presentations/Benitec_Biopharma_london.pdf
and it highlights where the company stands in terms of financial snapshot, technology timelines, and information on their flagship treatment, TT-034 for Hepatitis C. They also have potential treatments being developed in-house for Hepatitis B, Non Small Cell Lung Cancer (NSCLC), Cancer Associated Pain, Age-Related Macular Degeneration, and Oculopharangeal Muscular Dystrophy. They have out-licensed their technology to Calimmune for HIV, Regen Biopharma for potential Cancer Vaccine (Regen is currently is spinning off of Bio-Matrix Scientific Group, their majority shareholder), Genable for Retinitis Pigmentosa, and UniQure for Huntington’s Disease.
The VIDEO portion of their latest Spotlight Presentation can be watched here:http://www.finnewsnetwork.com.au/archives/finance_news_network76292.html
Numerous articles detailing why Benitec has so much potential for revolutionizing how we treat diseases, and as a company itself, can be seen here:
http://seekingalpha.com/instablog/24166073-24166073/2773743-why-benitec-biopharma-bnikf-has-a-very-bright-future-ahead
It also details insights from the author on what very KEY points were made during the investor Briefing that took place this March as well.
Another article detailing more about Benitec’s patented ddRNAi tech can be read here:
http://seekingalpha.com/instablog/19837781-pannobhaso/2771933-ddrnai-is-in-the-eye-of-the-beholder?source=kizur_seekingalpha
Benitec as a company that has the potential to dramatically change the cost of healthcare can be read here:
http://seekingalpha.com/article/2083973-benitec-the-health-payers-dream-biotech
How Benitec’s method of ddRNAi is distinct from the typical RNAi treatment can be read here:
http://seekingalpha.com/article/2054223-benitec-an-undiscovered-biotechnology-with-a-twist
Benitec’s treatment for lung cancer is another avenue that is currently being worked on, and is detailed in a Youtube video from UNSW Australia… and can be watched here:
If you’re interested in viewing an Australian Stock Blog like Investorhub, you can view this one:http://www.topstocks.com.au/new_asx_stock_forum.php
as well as this one: http://hotcopper.com.au/search_do.asp?fid=1&symbol=382
Here is a YouTube link regarding Tye Olson, one of the indivuals who is doing the Calimmune HIV trial using altered T-Cells with Benitec’s Tech. His trial is mentioned starting at around 6:20. This video was posted 04/14/2014.
Here is the update on the clinical trial on TT-034 as of May 12, 2014.
http://www.asx.com.au/asxpdf/20140512/pdf/42pkng61rx74k0.pdf
as well as the audio presentation with Dr. Peter French that can be heard here:http://www.brr.com.au/event/123347
A gene therapy presentation in regards to a cure for HIV can be seen here: www.isheid.com/presentations/mercredi/16-00/hutter/hutter.pdf
On June 25, 2014, a PR was released announcing that Calimmune has been given the green light to treat its second group in the HIV gene therapy trial. That announcement can be seen here:http://www.businesswire.com/news/home/20140625005962/en/Calimmune-Approved-Treat-Group-HIV-Stem-Cell#.U8HG3PldXzc
As of 5-29-2014, Benitec has also announced it has chosen New York Bank of Mellon as its authorized U.S. representative and Depository Bank to establish an ADR (American Depositary Receipt) Facility. The announcement can be seen here: http://www.benitec.com/documents/140530USADRTOBEESTABLISHED.pdf
Other ddRNAi programs are potentially in the works for possibly ALS and can be read in a blog here: http://seekingalpha.com/author/pannobhaso/instablog
I will try to continually update this post when new information comes out. Again, Welcome!
Blane
Recent BNTC News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/06/2024 05:15:18 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 09:19:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/21/2023 12:05:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/21/2023 12:00:53 PM
- Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 09:26:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 09:13:45 PM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM